Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

BioChain In-licenses China Rights to Colorectal Cancer Test

publication date: Oct 31, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
BioChain, a US-China clinical diagnostics company, acquired exclusive China rights to the Septin9 in vitro diagnostic test for colorectal cancer from Epigenomics AG of Germany. As part of the deal, BioChain will buy $1.3 million Epigenomics stock. It will also underwrite a China clinical trial of the device to obtain CFDA approval, for which it agreed to buy 5,000 Epi proColon® tests. In China, BioChain is located in Beijing. More details....

Stock Symbol: (F: ECX, OTC: EPGNY)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners